Based primarily in Kazan, Tatarstan, Russia, the Kazan State Medical University is a federal university made up of nine faculties. The university got the license on 6 March 1994 by the State Committee of the Russian Federation of Higher Education.

During the past decade, Kazan State Medical University conducted 58 clinical trials. In the 10-year time frame, 58 clinical trials started and 31 clinical trials were completed, i.e. on average, 53.4% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 27 clinical trials were completed. i.e. 142.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kazan State Medical University" #1 sponsor was "Materia Medica Holding" with 11 trials, followed by "Biocad" with 4 trials sponsored, "Janssen Research & Development, LLC" with 4 trials sponsored, "Takeda" with 4 trials sponsored and "Allergan" with 4 trials sponsored. Other sponsors include 43 different institutions and companies that sponsored additional 39 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kazan State Medical University" #1 collaborator was "Atlant Clinical Ltd." with 2 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator, "Cytel Inc." with 1 trials as a collaborator, "Datamap" with 1 trials as a collaborator and "Eisai Limited" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Kazan State Medical University" are "Ulcerative Colitis" (11 trials), "Colitis, Ulcerative" (5 trials), "Crohn's Disease" (5 trials), "Common Cold" (3 trials) and "Gastroparesis" (3 trials). Many other conditions were trialed in "Kazan State Medical University" in a lesser frequency.

Most popular intervention types in "Kazan State Medical University" are "Drug" (69 trials), "Other" (7 trials), "Biological" (4 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (37 trials), "Etrasimod" (3 trials), "Ustekinumab" (3 trials), "placebo" (3 trials) and "Ergoferon" (2 trials). Other intervention names were less common.

The vast majority of trials in "Kazan State Medical University" are 69 trials for "All" genders, 4 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Kazan State Medical University". undefined are not yet recruiting, 11 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 40 completed trials in Kazan State Medical University, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Kazan State Medical University, 1 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 50 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 0 trials that are defined as “Not Applicable".

Kazan State Medical University has several departments that took part in Clinical trials: "Kazan State Medical University, Internal Medicine Department" - 2 trials, "Kazan State Medical University, Department of Propedeutics of Internal Diseases named after prof. S.S. Zimnitsky" - 2 trials